Browse by category

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient

There have been reports that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may also have the potential to treat alcohol and drug...

The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, according to research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25). GLP-1 receptor agonists are now widely prescribed for individuals with type 2 diabetes and weight loss, with a 700% increase in usage reported in the US between 2019 and 2023. These medications alter glucose metabolism, gastric motility and sympathetic to

High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...

High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, according to a presentation, ‘Visceral...

There has been a 16-fold increase in the use of weight loss drugs among patients before metabolic and bariatric surgery, signalling an...